Lovastatin

Origin and chemical structure

Lovastatin is a natural statin isolated from the fungal culture Aspergillus terreus. It later served as the chemical basis for the development of semisynthetic analogues (simvastatin and pravastatin).

The structure of the drug strictly determines its pharmacological activity (SAR):

• Hydronaphthalene ring — a key element providing binding to the enzyme HMG-CoA reductase.
• Side chain (represented by a hydroxy acid) — imparts structural similarity to mevalonate, which is the natural substrate for this enzyme.

Mechanism of action

Pharmacologically, lovastatin is a prodrug. In the tablet, it is present as an inactive lactone. Upon entering the body, the drug undergoes hydrolysis and is converted into the pharmacologically active $\beta$-hydroxy acid.

Inhibition of cholesterol synthesis occurs strictly inside hepatocytes. For the drug to reach its target, the hepatic transporter OATP1B1 is required. It ensures the active uptake of the statin from the blood into the liver during the first pass. The function of this transporter has a dual significance:

1. Therapeutic: delivery of the drug directly to the site of action to ensure efficacy.
2. Toxicological: a sharp reduction in the drug concentration in the systemic circulation, which prevents the development of systemic side effects (primarily myopathy).

Pharmacokinetics

Upon oral administration, the bioavailability of lovastatin is extremely low (less than 5% — the lowest value in the statin group). This is due to pronounced presystemic metabolism in the liver (first-pass effect).

• Effect of food: unlike pravastatin and fluvastatin, the bioavailability of lovastatin increases when taken after a meal.
• Time parameters: maximum plasma concentration ($T_{max}$) is reached slowly — in 2–4 hours.
• Distribution: the drug has high lipophilicity, due to which it readily penetrates histohematic barriers, including the blood-brain barrier (BBB) and the placenta.

Drug interactions (CYP3A4)

Lovastatin is metabolized by the most extensive group of cytochrome P450 isoenzymes — CYP3A4 / CYP3A5. This requires careful evaluation of concomitant therapy, as changes in enzyme activity directly affect treatment safety.

• CYP3A4 inhibitors slow down the breakdown of the statin. This leads to drug accumulation in the blood and a sharp increase in the risk of myopathy. Strong inhibitors include: antifungal azoles (ketoconazole), macrolides (erythromycin, clarithromycin), cardiac drugs (verapamil, diltiazem, quinidine), antivirals (ritonavir), as well as dietary components — furanocoumarins in grapefruit juice.
• CYP3A4 inducers accelerate drug elimination, reducing its therapeutic efficacy. These include: antiepileptic drugs (carbamazepine, phenytoin, barbiturates), the antibiotic rifampicin, glucocorticoids, and herbal products (St. John's wort herb containing hyperforin).

Prescription and administration

The drug is prescribed orally. The standard therapeutic dosage range is 0.02–0.04 g.

Example of a prescription for 20 mg (0.02 g) tablets:

Rp.: Tab. Lovastatini 0.02 D.t.d. N. 30 S. Take orally 1 tablet once a day (after meals).

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Comparative pharmacokinetics of statins: bioavailability, food effect, and $T_{max}$.
• The role of CYP3A4/CYP3A5 isoenzymes in the metabolism of cardiac drugs.
• Organic anion transporters (OATP) and their toxicological significance.
• Mechanism of development of statin-induced myopathy.
• The effect of lipophilicity on drug penetration across histohematic barriers.

Other topics in the «Drugs and Prescriptions» section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.